XML 61 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company has one reportable segment relating to the development of immunotherapies for patients with limited treatment options and poor outcomes suffering from cancer. The Company’s CODM, its Chief Executive Officer, manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, and the change in fair value of warrants are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the consolidated statements of cash flows.
Other segment items include interest revenue, interest expense, change in the fair value of derivatives, and change in the fair value of warrants. Expenditures for additions to long-lived assets, which include purchases of property and equipment, are included in total consolidated assets reviewed by the CODM and are reported on the consolidated statements of cash flows. The following table presents certain financial data for the Company’s reportable segment (in thousands):
December 31,
20242023
Clinical trial expenses $15,892 $7,066 
Employee related research and development expenses8,560 7,306 
Chemistry, manufacturing and controls expenses4,260 7,623 
Other research and development expenses5,971 5,553 
Contract and grant reimbursements(1,027)(3,800)
Employee related general and administrative expenses3,682 3,437 
Professional fees and other general and administrative expenses 7,648 8,455 
Other segment items 6,912 (445)
Segment net loss$51,898 $35,195 
Total segment assets$28,178 $27,146